MESO Quote, Financials, Valuation and Earnings

Immutep has a net margin of -- compared to Mesoblast's net margin of --. Mesoblast's return on equity of -- beat Immutep's return on equity of --.

Mesoblast has a consensus price target of $22.50, signalling upside risk potential of 32.2%. On the other hand Immutep has an analysts' consensus of $8.43 which suggests that it could grow by 387.18%. Given that Immutep has higher upside potential than Mesoblast, analysts believe Immutep is more attractive than Mesoblast.

Mesoblast has a beta of 3.540, which suggesting that the stock is 253.97% more volatile than S&P 500. In comparison Immutep has a beta of 2.221, suggesting its more volatile than the S&P 500 by 122.066%.

Mesoblast has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast pays -- of its earnings as a dividend. Immutep pays out -- of its earnings as a dividend.

Mesoblast quarterly revenues are --, which are smaller than Immutep quarterly revenues of --. Mesoblast's net income of -- is lower than Immutep's net income of --. Notably, Mesoblast's price-to-earnings ratio is -- while Immutep's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast is 176.48x versus -- for Immutep. Usually stocks with elevated PS ratios are considered overvalued.

Immuron has a net margin of -- compared to Mesoblast's net margin of --. Mesoblast's return on equity of -- beat Immuron's return on equity of -40.9%.

Mesoblast has a consensus price target of $22.50, signalling upside risk potential of 32.2%. On the other hand Immuron has an analysts' consensus of -- which suggests that it could grow by 157.76%. Given that Immuron has higher upside potential than Mesoblast, analysts believe Immuron is more attractive than Mesoblast.

Mesoblast has a beta of 3.540, which suggesting that the stock is 253.97% more volatile than S&P 500. In comparison Immuron has a beta of 1.352, suggesting its more volatile than the S&P 500 by 35.224%.

Mesoblast has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast pays -- of its earnings as a dividend. Immuron pays out -- of its earnings as a dividend.

Mesoblast quarterly revenues are --, which are smaller than Immuron quarterly revenues of --. Mesoblast's net income of -- is lower than Immuron's net income of --. Notably, Mesoblast's price-to-earnings ratio is -- while Immuron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast is 176.48x versus 3.44x for Immuron. Usually stocks with elevated PS ratios are considered overvalued.

Kazia Therapeutics has a net margin of -- compared to Mesoblast's net margin of --. Mesoblast's return on equity of -- beat Kazia Therapeutics's return on equity of -1083.16%.

Mesoblast has a consensus price target of $22.50, signalling upside risk potential of 32.2%. On the other hand Kazia Therapeutics has an analysts' consensus of -- which suggests that it could grow by 586.69%. Given that Kazia Therapeutics has higher upside potential than Mesoblast, analysts believe Kazia Therapeutics is more attractive than Mesoblast.

Mesoblast has a beta of 3.540, which suggesting that the stock is 253.97% more volatile than S&P 500. In comparison Kazia Therapeutics has a beta of 1.977, suggesting its more volatile than the S&P 500 by 97.738%.

Mesoblast has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast pays -- of its earnings as a dividend. Kazia Therapeutics pays out -- of its earnings as a dividend.

Mesoblast quarterly revenues are --, which are smaller than Kazia Therapeutics quarterly revenues of --. Mesoblast's net income of -- is lower than Kazia Therapeutics's net income of --. Notably, Mesoblast's price-to-earnings ratio is -- while Kazia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast is 176.48x versus -- for Kazia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Opthea has a net margin of -- compared to Mesoblast's net margin of --. Mesoblast's return on equity of -- beat Opthea's return on equity of --.

Mesoblast has a consensus price target of $22.50, signalling upside risk potential of 32.2%. On the other hand Opthea has an analysts' consensus of $12.17 which suggests that it could grow by 235.17%. Given that Opthea has higher upside potential than Mesoblast, analysts believe Opthea is more attractive than Mesoblast.

Mesoblast has a beta of 3.540, which suggesting that the stock is 253.97% more volatile than S&P 500. In comparison Opthea has a beta of 0.742, suggesting its less volatile than the S&P 500 by 25.8%.

Mesoblast has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Opthea offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesoblast pays -- of its earnings as a dividend. Opthea pays out -- of its earnings as a dividend.

Mesoblast quarterly revenues are --, which are smaller than Opthea quarterly revenues of --. Mesoblast's net income of -- is lower than Opthea's net income of --. Notably, Mesoblast's price-to-earnings ratio is -- while Opthea's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesoblast is 176.48x versus 2,322.88x for Opthea. Usually stocks with elevated PS ratios are considered overvalued.